Literature DB >> 15708124

Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: possible implications in the process of trophoblast apoptosis.

H Lee1, H Park, Y J Kim, H J Kim, Y M Ahn, B Park, J H Park, B Eun Lee.   

Abstract

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) was originally identified as a receptor for oxidatively modified low-density lipoprotein. It has been reported that oxidative stress and hyperlipidemia play important roles in the etiology of preeclampsia, and that placental oxidative stress may stimulate syncytiotrophoblast apoptosis in preeclampsia. In this study, we examined the expression of LOX-1 in the human placentas of normal pregnancies and in preeclampsia using immunohistochemistry and Western blot analysis, and proposed that LOX-1 has a role in trophoblast apoptosis. To analyze apoptotic activity, the expression of the specific caspase cleavage site within cytokeratin 18 was assessed immunohistochemically using the monoclonal antibody M30 CytoDeath. Both LOX-1 and M30 immunoreactivity occurred predominantly in syncytiotrophoblasts. A significantly higher number of LOX-1 and M30-positive cells were found in preeclamptic placentas than in normal placentas. The number of M30-positive cells correlated with the apoptotic index of trophoblasts determined by TdT-mediated dUTP nick-end labeling (TUNEL). Syncytiotrophoblasts showing apoptotic activity were immunopositive to LOX-1 by double immunohistochemical fluorescence. We suggest that the functional role of syncytiotrophoblasts in placental dysfunction results from the localization and upregulation of LOX-1 in the preeclamptic placenta, possible implications in upregulation of syncytiotrophoblast apoptotic activity in preeclampsia. (c) Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708124     DOI: 10.1016/j.placenta.2004.05.012

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  7 in total

1.  Increased oxidized low-density lipoprotein causes blood-brain barrier disruption in early-onset preeclampsia through LOX-1.

Authors:  Malou P H Schreurs; Carl A Hubel; Ira M Bernstein; Arun Jeyabalan; Marilyn J Cipolla
Journal:  FASEB J       Date:  2012-12-10       Impact factor: 5.191

2.  Expression and localization of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in murine and human placentas.

Authors:  Hiroo Satoh; Emi Kiyota; Yasuhiro Terasaki; Tatsuya Sawamura; Katsumasa Takagi; Hiroshi Mizuta; Motohiro Takeya
Journal:  J Histochem Cytochem       Date:  2008-05-12       Impact factor: 2.479

Review 3.  Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms.

Authors:  Frank T Spradley; Ana C Palei; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

4.  Comparative proteomics analysis of placenta from pregnant women with intrahepatic cholestasis of pregnancy.

Authors:  Ting Zhang; Yueshuai Guo; Xuejiang Guo; Tao Zhou; Daozhen Chen; Jingying Xiang; Zuomin Zhou
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 5.  Role of lectin-like oxidized low density lipoprotein-1 in fetoplacental vascular dysfunction in preeclampsia.

Authors:  Felipe A Zuniga; Valeska Ormazabal; Nicolas Gutierrez; Valeria Aguilera; Claudia Radojkovic; Carlos Veas; Carlos Escudero; Liliana Lamperti; Claudio Aguayo
Journal:  Biomed Res Int       Date:  2014-07-06       Impact factor: 3.411

Review 6.  Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.

Authors:  Jonathan De Siqueira; Izma Abdul Zani; David A Russell; Stephen B Wheatcroft; Sreenivasan Ponnambalam; Shervanthi Homer-Vanniasinkam
Journal:  J Cardiovasc Transl Res       Date:  2015-09-18       Impact factor: 4.132

Review 7.  Placental disease and the maternal syndrome of preeclampsia: missing links?

Authors:  Dionne Tannetta; Ian Sargent
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.